Get caught up quickly on the top news and calls moving stocks with these Top Fives, as compiled by the editors of The Fly. 

1. STOCK NEWS: 

• Salesforce (CRM) provided a "beat and raise" report for Q3 [more]
• Exxon Mobil (XOM) will maintain capital investments of $20B-$25B through 2027 [more]
  
• HP Enterprise (HPE) reported upbeat Q4 results [more]
  
• The FDA's Antimicrobial Drugs Advisory Committee voted to recommend Merck (MRK) and Ridgeback's COVID antiviral drug [more]
  
• Zscaler (ZS) reported upbeat Q1 earnings and revenue [more]
  

2. WALL STREET CALLS: 

• Krispy Kreme (DNUT) downgraded to Sell from Neutral at Goldman Sachs [more]
• Gordon Haskett sees "compelling re-entry point," upgrades DoorDash (DASH) to Buy [more]
  
• Capital One (COF) upgraded to Neutral after underperformance at Baird [more]
  
• D.R. Horton (DHI) downgraded to Neutral from Buy at Goldman Sachs [more]
  
• Lennar (LEN) upgraded to Buy from Neutral at Goldman Sachs [more]
  

3. AROUND THE WEB: 

• UniCredit (UNCRY) anticipates 3,000 job cuts, Bloomberg reports [more]
• Byron Allen's $10B McDonald's (MCD) discrimination suit has been thrown out, Reuters reports [more]
  
• Microsoft (MSFT) shareholders approved a sexual harassment disclosure proposal, WSJ says [more]
  
• Stellantis (STLA) CEO Carlos Tavares said the EV cost burden "is beyond the limits," Reuters reports [more]
  
• 23andMe (ME) is developing immuno-oncology drugs with SPAC cash, WSJ reports [more]
  

4. MOVERS: 

• Arbutus Biopharma (ABUS) jumps after Moderna (MRNA) denied appeal in drug delivery patent fight [more]
• ImmunoGen (IMGN) rises after Jefferies analyst Kelly Shi upgraded the stock to Buy from Hold [more]
  
• Build-A-Bear (BBW) and G-III Apparel (GIII) higher after reporting quarterly results [more]
  
• BeyondSpring (BYSI) falls after the FDA determined that the plinabulin NDA cannot be approved in its present form [more]
  
• CTI BioPharma (CTIC) lower after announcing the FDA has extended the review period for the new drug application for pacritinib for the treatment of adult patients with intermediate or high-risk primary or secondary myelofibrosis [more]
  

5. EARNINGS/GUIDANCE: 

• Allbirds (BIRD) slips after first report since coming public [more]
• Box (BOX) reported upbeat Q3 results and expanded its stock buyback program [more]
  
• GlobalFoundries (GFS) reported what Morgan Stanley called a "solid" first report since coming public [more]
  
• Ambarella (AMBA) reported upbeat Q3 results [more]
  
• Celestica (CLS) reaffirmed its Q4 earnings and revenue guidance [more]
  

INDEXES: 

Near midday, the Dow was up 458.49, or 1.33%, to 34,942.21, the Nasdaq was up 239.05, or 1.54%, to 15,776.74, and the S&P 500 was up 78.90, or 1.73%, to 4,645.90.